ACURATE neo2 TAVI achieves high success in severe bicuspid aortic stenosis, demonstrating strong 30-day safety and efficacy.

Women are often underdiagnosed and undertreated when it comes to heart disease, particularly conditions like aortic stenosis.

Q4 2024 Earnings Call Transcript February 11, 2025 Edwards Lifesciences Corporation beats earnings expectations. Reported EPS ...

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

Edwards Lifesciences Corporation (NYSE:EW) develops medical innovations for heart disease and critical care monitoring. Its ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Investors remain bullish on medical device makers, expecting them to benefit from still-high demand for surgical procedures, ...

IRVINE, Calif. - Edwards Lifesciences (NYSE:EW) reported fourth quarter earnings and revenue that beat analyst expectations, sending its shares up 4.2% in after-hours trading on Tuesday.

Edwards Lifesciences had a higher profit and sales in its fourth quarter as demand for its products held strong. The medical-technology company posted a profit of $385.6 million, or 65 cents a share, ...